Tyrosine kinase inhibitorPhase 3 trialInvestigational
Ceritinib
How it works
Blocks ALK in cancer cells, preventing uncontrolled growth.
Cancer types
Lung Cancer— ALK-positive
Melanoma— ALK-positive
Efficacy
In clinical trials, around 60% of patients achieved an objective response, with median progression-free survival of approximately 16.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.